In this issue of Clinical Cancer Research, evidence is provided on how to avoid cardiotoxicity when targeting hERG K+ channel for cancer therapy. hERG regulates different aspects of neoplastic progression. Although its blockade has effective anticancer effects in experimental models, it may lead to fatal arrhythmias in humans.
Arcangeli, A., Becchetti, A. (2017). hERG Channels: From Antitargets to Novel Targets for Cancer Therapy. CLINICAL CANCER RESEARCH, 23(1), 3-5 [10.1158/1078-0432.CCR-16-2322].
hERG Channels: From Antitargets to Novel Targets for Cancer Therapy
BECCHETTI, ANDREAUltimo
2017
Abstract
In this issue of Clinical Cancer Research, evidence is provided on how to avoid cardiotoxicity when targeting hERG K+ channel for cancer therapy. hERG regulates different aspects of neoplastic progression. Although its blockade has effective anticancer effects in experimental models, it may lead to fatal arrhythmias in humans.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
10281-141161.pdf
accesso aperto
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Dimensione
335.72 kB
Formato
Adobe PDF
|
335.72 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
